YAR Stock Analysis: Yara International ASA | OL
Agricultural Inputs | OL, Norway | Market Cap: 104.948m NOK | 12M Return: 13.2% | NO0010208051 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 202M
EPS Trend: 73.3%
Qual. Beats: -1
Rev. Trend: 14.9%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Yara International ASA, founded in 1905 and headquartered in Oslo, Norway, is a global provider of crop nutrition, ammonia, and industrial solutions operating across Europe, Africa, Asia, the Americas, and Oceania. The company offers an extensive fertilizer portfolio spanning ammonium- and urea-based products, compound NPK fertilizers, nitrate and calcium nitrate products, micronutrients, biostimulants, organic-based and climate-choice fertilizers, as well as coatings and foliar/fertigation solutions. Alongside its core products, Yara has built out a digital agritech ecosystem-including tools like YaraFX Insight, N-sensors, N-Tester, Atfarm, YaraPlus, and various e-commerce and farm-management platforms-designed to support precision agriculture and crop nutrition decision-making. Its products are marketed under multiple brands, including YaraBela, YaraMila, YaraLiva, YaraVita, YaraAmplix, YaraRega, YaraTera, YaraSuna, and YaraVera.
As one of the worlds largest fertilizer producers, Yara plays a central role in the global agricultural inputs value chain, where nitrogen-based fertilizers are critical to sustaining crop yields and food security. The companys combination of traditional fertilizer manufacturing with digital farming tools reflects a broader industry shift toward precision agriculture, which uses data and sensor technology to optimize nutrient application, reduce waste, and lower environmental impact.
- European natural gas prices pressure nitrogen production margins
- Premium specialty fertilizer segment expands margins and revenue mix
- Global nitrogen supply discipline supports urea and ammonia pricing
| Net Income: 1.53b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.75 > 1.0 |
| NWC/Revenue: 19.86% < 20% (prev 17.60%; Δ 2.26% < -1%) |
| CFO/TA 0.27 > 3% & CFO 4.65b > Net Income 1.53b |
| Net Debt (-165.0m) to EBITDA (3.15b): -0.05 < 3 |
| Current Ratio: 1.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (254.7m) vs 12m ago -0.00% < -2% |
| Gross Margin: 30.01% > 18% (prev 27.45%; Δ 2.56% > 0.5%) |
| Asset Turnover: 96.16% > 50% (prev 86.37%; Δ 9.80% > 0%) |
| Interest Coverage Ratio: 7.97 > 6 (EBIT TTM 2.06b / Interest Expense TTM 259.0m) |
| A: 0.19 (Total Current Assets 7.49b - Total Current Liabilities 4.21b) / Total Assets 17.5b |
| B: 0.62 (Retained Earnings 10.9b / Total Assets 17.5b) |
| C: 0.12 (EBIT TTM 2.06b / Avg Total Assets 17.2b) |
| D: 1.06 (Book Value of Equity 9.01b / Total Liabilities 8.47b) |
| Altman-Z'' = 5.19 = AAA |
| DSRI: 0.90 (Receivables 1.99b/1.94b, Revenue 16.5b/14.6b) |
| GMI: 0.91 (GM 27.45% / 30.01%) |
| AQI: 0.90 (AQ_t 0.11 / AQ_t-1 0.13) |
| SGI: 1.13 (Revenue 16.5b / 14.6b) |
| TATA: -0.18 (NI 1.53b - CFO 4.65b) / TA 17.5b) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of October 21, 2026, the stock is trading at NOK 408.00 with a total of 389,457 shares traded. Over the past week, the price has changed by +1.90%, over one month by -9.85%, over three months by -8.87% and over the past year by +13.22%.
Current recommended Stop Loss: 393.70 (which is 3.5% or 1.4 ATR below the current price).
Yara International ASA has no consensus analysts rating.
Market Cap USD = 11.1b (105b NOK * 0.1062 NOK.USD)
P/E Trailing = 6.9682
P/E Forward = 8.7566
P/S = 6.3447
P/B = 1.3657
P/EG = 2.5338
Revenue TTM = 16.5b USD
EBIT TTM = 2.06b USD
EBITDA TTM = 3.15b USD
Long Term Debt = 2.78b USD (from longTermDebt, last quarter)
Short Term Debt = 449.0m USD (from shortLongTermDebt, last quarter)
Debt = 540.0m USD (Leases only: 540.0m)
Net Debt = -165.0m USD (calculated: Debt 540.0m - CCE 705.0m)
Enterprise Value = 11.0b USD (11.1b + Debt 540.0m - CCE 705.0m)
Interest Coverage Ratio = 7.97 (Ebit TTM 2.06b / Interest Expense TTM 259.0m)
EV/FCF = 11.49x (Enterprise Value 11.0b / FCF TTM 956.0m)
FCF Yield = 8.71% (FCF TTM 956.0m / Enterprise Value 11.0b)
FCF Margin = 5.78% (FCF TTM 956.0m / Revenue TTM 16.5b)
Net Margin = 9.27% (Net Income TTM 1.53b / Revenue TTM 16.5b)
Gross Margin = 30.01% ((Revenue TTM 16.5b - Cost of Revenue TTM 11.6b) / Revenue TTM)
Gross Margin QoQ = 31.12% (prev 30.34%)
Tobins Q-Ratio = 0.63 (Enterprise Value 11.0b / Total Assets 17.5b)
Interest Expense / Debt = 47.96% (Interest Expense 259.0m / Debt 540.0m)
Taxrate = 22.53% (447.0m / 1.98b)
NOPAT = 1.60b (EBIT 2.06b * (1 - 22.53%))
Current Ratio = 1.78 (Total Current Assets 7.49b / Total Current Liabilities 4.21b)
Debt / Equity = 0.06 (Debt 540.0m / totalStockholderEquity, last quarter 9.01b)
Debt / EBITDA = -0.05 (Net Debt -165.0m / EBITDA 3.15b)
Debt / FCF = -0.17 (Net Debt -165.0m / FCF TTM 956.0m)
Total Stockholder Equity = 8.81b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.91% (Net Income 1.53b / Total Assets 17.5b)
RoE = 17.41% (Net Income TTM 1.53b / Total Stockholder Equity 8.81b)
RoCE = 17.81% (EBIT 2.06b / Capital Employed (Equity 8.81b + L.T.Debt 2.78b))
RoIC = 12.58% (NOPAT 1.60b / Invested Capital 12.7b)
WACC = 6.92% (E(11.1b)/V(11.7b) * Re(5.45%) + D(540.0m)/V(11.7b) * Rd(47.96%) * (1-Tc(0.23)))
Discount Rate = 5.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 77.97% ; FCFF base≈824.8m ; Y1≈945.5m ; Y5≈1.39b
[DCF] Fair Price = 82.87 (EV 20.9b - Net Debt -165.0m = Equity 21.1b / Shares 254.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 73.25 | EPS CAGR: 138.6% | SUE: -3.74 | # QB: -1
Revenue Correlation: 14.88 | Revenue CAGR: 1.21% | SUE: -0.98 | # QB: -1
EPS current Quarter (2026-09-30): EPS=12.09 | Chg30d=-11.23% | Revisions=-25% | Analysts=6
EPS current Year (2026-12-31): EPS=55.31 | Chg30d=-5.77% | Revisions=-31% | GrowthEPS=+31.4% | GrowthRev=+10.3%
EPS next Year (2027-12-31): EPS=46.79 | Chg30d=+1.23% | Revisions=+31% | GrowthEPS=-15.4% | GrowthRev=-2.5%
[Analyst] Revisions Ratio: -4% (up=10, down=11)